Down Stocks to Buy and Hold for the Next 10 Years
Medtronic (MDT) reported Q1 2027 revenue of $9.8B, up 13.7% YoY, and raised full-year guidance. Despite a 2% YTD decline, its long-term growth prospects and dividend history make it attractive. MercadoLibre (MELI) saw Q2 revenue rise 50% YoY to $10.2B but EPS fell due to investments. Its initiatives aim to strengthen its market position and moat.
How this was made
The 30-second read
Why it matters
Earnings beats and guidance upgrades provide fresh catalysts for price moves, while strategic investments shape future growth trajectories.
Market read
Both stocks show material earnings news that can influence sector sentiment and investor positioning.
What to watch
Potential regulatory scrutiny on Medtronic's device pipeline; currency fluctuations could impact MercadoLibre's earnings.
Background
The article reviews two large-cap stocks as long‑term buy‑and‑hold candidates, focusing on recent earnings releases and strategic initiatives.
Ticker impact
Medtronic reported Q1 2027 revenue of $9.8B (+13.7% YoY) and EPS $1.45 (+15.1% YoY) with raised guidance, marking a beat‑and‑raise quarter.
upward pressure in the near term, potential continuation of upside if guidance holds.
Large‑cap medical device firm with strong earnings surprise and dividend growth; market typically rewards such beats.
MercadoLibre posted Q2 revenue of $10.2B (+~50% YoY) but EPS fell to $9.19 from $10.31, reflecting higher costs from free‑shipping and fintech expansion.
mixed; potential bounce if investors focus on top‑line growth, but downside risk from margin compression.
Strong revenue growth in a high‑growth market, but earnings miss could temper enthusiasm.
Market effects
Positive earnings may lift broader medical‑device sector; MercadoLibre's growth underscores strength in Latin American e‑commerce and fintech.
Medtronic's results support US healthcare equities; MercadoLibre's performance influences Latin America market sentiment.
Both companies are large caps with global exposure, affecting investor risk‑on sentiment.
Counterpoint
Medtronic's valuation may already price in growth, limiting upside; MercadoLibre's margin pressure could signal overextension.
Key entities
- CompanyMedtronic
Medical device manufacturer reporting strong Q1 2027 results.
- CompanyMercadoLibre
Latin American e‑commerce and fintech platform reporting Q2 revenue surge.
